Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens ; however , their comparative effectiveness when partnered with first-line fluorouracil , folinic acid , and irinotecan ( FOLFIRI ) is unknown .